Hamed Kamal's Form 4 filing
Spero Therapeutics, Inc.SPRO · filed Feb 5, 2024
- Accession no.
- 0000950170-24-011491
- Filed
- Feb 5, 2024
- Trade date
- Feb 1-2, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $38.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hamed KamalCIK 0001946366 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Common Stock | AGrant or awardAcquired | +239,731 | $0.00 | $0 | 816,192 | Direct | |
| Feb 2, 2024 | Common Stock | SSaleDisposed | −28,075 | $1.37F3 | −$38,462.75 | 788,117 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.